Shares of Virpax Pharmaceuticals Inc. (VRPX) are down more than 80% from their high of $36, recorded in August of this year, and trade around $4.
The company is developing product candidates for pain management, neurological conditions, and viral infections.
The lead product candidate is Envelta, an endogenous enkephalin intranasal spray for acute and chronic pain. It is under IND-enabling studies that are being conducted in partnership with the National Institutes of Health (NIH).
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.